New class of drug leads to 30% reduced risk of death for bladder cancer patients
A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial
2021-02-12
(Press-News.org) A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial led in the UK by Queen Mary University of London and Barts Health NHS Trust.
The results are published in the New England Journal of Medicine and were presented at the 2021 American Society of Clinical Oncology's Genitourinary Cancers Symposium.
Urothelial cancer is the most common type of bladder cancer (90 percent of cases) and can also be found in the renal pelvis (where urine collects inside the kidney), ureter (tube that connects the kidneys to the bladder) and urethra. Globally, approximately 549,000 new cases of bladder cancer and 200,000 deaths are reported annually.
One of the most widely used treatments for this type of cancer is chemotherapy which works by targeting all the cells in the body, successfully acting upon cancer cells, but also affecting non-cancer cells, causing side effects.
A new class of drugs known as 'antibody-drug conjugates' (ADC) work by having an antibody attached to a chemotherapy-like drug. The antibody specifically targets and attaches to the cancer cells, bringing with it the chemotherapy-like drug, allowing it to only act upon those cancer cells and ignore normal cells in the body.
The trial involved 608 patients in 19 countries and tested a new ADC drug enfortumab vedotin, developed by Astellas Pharma Inc. and Seagen Inc., in adult patients with locally advanced or metastatic urothelial cancer who were previously treated with platinum-based chemotherapy and an immunotherapy drug called a PD-1/L1 inhibitor. It found that:
The risk of death was 30 per cent lower with the new drug than with chemotherapy, with a median survival of approximately 13 months for the new drug.
Median progression-free survival, which is the time without progression of cancer, was 5.6 months for the new drug vs. 3.7 months for chemotherapy
Overall response rate, the percentage of patients with either complete or partial response, was 40.6 percent vs. 17.9 percent of patients in the chemotherapy arm
The side effects of the drug were manageable and overall similar to chemotherapy.
Lead UK researcher, Tom Powles, Professor of Genitourinary Oncology at Queen Mary University of London, and Director of Barts Cancer Centre, Barts Health NHS Trust, said: "This new type of drug has led to a survival advantage in bladder cancer which has been difficult to achieve in this difficult disease. It reduced the death rate by 30 per cent and beat chemotherapy in every setting, so this really is a big deal."
INFORMATION:
Enfortumab vedotin was also found to have a tolerable safety profile. Side effects included pins and needles and a skin rash, which the research team say require careful management.
The drug is already available in the US after the Food and Drug Administration gave it accelerated approval and is currently awaiting regulatory approval in the UK. Researchers say it could be available to NHS patients in a few months if it goes through the Early Access Medicine Scheme (EAMS).
For more information, please contact:
Joel Winston
Communications Manager (School of Medicine and Dentistry)
Queen Mary University of London
j.winston@qmul.ac.uk
Tel: +44 (0)7968 267 064
Notes to the editor
* Research paper: 'Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma'. Thomas Powles, M.D., Jonathan E. Rosenberg, M.D., Guru P. Sonpavde, M.D., Yohann Loriot, M.D., Ph.D., Ignacio Durán, M.D., Ph.D., Jae-Lyun Lee, M.D., Ph.D., Nobuaki Matsubara, M.D., Christof Vulsteke, M.D., Ph.D., Daniel Castellano, M.D., Chunzhang Wu, Ph.D., Mary Campbell, M.D., Maria Matsangou, M.B., Ch.B., M.D., and Daniel P. Petrylak, M.D.
New England Journal of Medicine. DOI: 10.1056/NEJMoa2035807
Available here after the embargo lifts:
http://www.nejm.org/doi/full/10.1056/NEJMoa2035807
About Queen Mary University of London
At Queen Mary University of London, we believe that a diversity of ideas helps us achieve the previously unthinkable.
In 1785, Sir William Blizard established England's first medical school, The London Hospital Medical College, to improve the health of east London's inhabitants. Together with St Bartholomew's Medical College, founded by John Abernethy in 1843 to help those living in the City of London, these two historic institutions are the bedrock of Barts and The London School of Medicine and Dentistry.
Today, Barts and The London continues to uphold this commitment to pioneering medical education and research. Being firmly embedded within our east London community, and with an approach that is driven by the specific health needs of our diverse population, is what makes Barts and The London truly distinctive.
Our local community offer to us a window to the world, ensuring that our ground-breaking research in cancer, cardiovascular and inflammatory diseases, and population health not only dramatically improves the outcomes for patients in London, but also has a far-reaching global impact.
This is just one of the many ways in which Queen Mary is continuing to push the boundaries of teaching, research and clinical practice, and helping us to achieve the previously unthinkable.
ELSE PRESS RELEASES FROM THIS DATE:
2021-02-12
WORCESTER, Mass. -- New research by Christopher A. Williams, an environmental scientist and professor in Clark University's Graduate School of Geography, reveals that deforestation in the U.S. does not always cause planetary warming, as is commonly assumed; instead, in some places, it actually cools the planet. A peer-reviewed study by Williams and his team, "Climate Impacts of U.S. Forest Loss Span Net Warming to Net Cooling," published today (Feb. 12) in Science Advances. The team's discovery has important implications for policy and management efforts that are turning to forests to mitigate climate change.
It ...
2021-02-12
RIVERSIDE, Calif. -- Astrocytes -- star-shaped cells in the brain that are actively involved in brain function -- may play an important role in stuttering, a study led by a University of California, Riverside, expert on stuttering has found.
"Our study suggests that treatment with the medication risperidone leads to increased activity of the striatum in persons who stutter," said Dr. END ...
2021-02-12
HANOVER, N.H. - February 12, 2021 - A newly discovered planetary system will provide researchers with the rare chance to study a group of growing planets, according to research co-led by Dartmouth.
The new system, named TOI 451, is made up of at least three neighboring planets that orbit the same sun. The planets range in size between that of Earth and Neptune.
According to the research team, NASA's Hubble Space Telescope and its planned successor, the James Webb Space Telescope, can be used to study the atmosphere of each planet. Such research could lead to information on how planetary systems like our own solar system evolve.
"The sun in this planetary system is very similar to our own sun, but much younger," ...
2021-02-12
In your quest for true love and that elusive happily ever after, are you waiting for the "right" person to come along, or do you find yourself going for the cutest guy or girl in the room, hoping things will work out? Do you leave your options open, hoping to "trade-up" at the next opportunity, or do you invest in your relationship with an eye on the cost-benefits analysis?
For something so fundamental to our existence, mate selection remains one of humanity's most enduring mysteries. It's been the topic of intense psychological research for decades, spawning myriad hypotheses of why we choose whom we choose.
"Mate choice is really complicated, especially in humans," ...
2021-02-12
CHICAGO (February 12, 2021): Since 2010, National Institutes of Health (NIH) funding to support surgeon scientists has, remarkably, risen significantly while funding to support other non-surgeon physicians has significantly decreased. This growth has occurred despite an overall decrease in NIH funding and an increase in demand for clinical productivity. These findings are according to an " END ...
2021-02-12
Scientists at Lund University have discovered how E. coli bacteria target and degrade the well-known oncogene MYC, which is involved in many forms of cancer. The study is now published in Nature Biotechnology.
Cancer cells grow too fast, outcompete normal cells and spread to distant sites, where they cause metastases. Understanding what makes cancer cells so efficient and threatening is critically important and stopping them has always been the goal of cancer research. Early studies identified so-called ''oncogenes''; genes that that normally control cell growth but when mutated may be responsible for the creation of cancer cells and explain their competitive advantage.
The pleiotropic transcription factor MYC has been ...
2021-02-12
(BOSTON) -- Many life-threatening medical conditions, such as sepsis, which is triggered by blood-borne pathogens, cannot be detected accurately and quickly enough to initiate the right course of treatment. In patients that have been infected by an unknown pathogen and progress to overt sepsis, every additional hour that an effective antibiotic cannot be administered significantly increases the mortality rate, so time is of utmost essence.
The challenge with rapidly diagnosing sepsis stems from the fact that measuring only one biomarker often does not allow a clear-cut diagnosis. Engineers have struggled for decades to simultaneously quantify multiple biomarkers in whole blood with high ...
2021-02-12
The drug thalidomide was sold as a sedative under the trade name Contergan in the 1950s and 1960s. At the time, its side-effects triggered one of the largest pharmaceutical scandals in history: The medication was taken from the market after it became known that the use of Contergan during pregnancy had resulted in over 10,000 cases of severe birth defects.
Currently, the successor preparations lenalidomide and pomalidomide are prescribed under strict supervision by experienced oncologists - the active ingredients are a cornerstone of modern cancer therapies. The use of lenalidomide and pomalidomide has considerably improved the success ...
2021-02-12
EL PASO, Texas - Science is a step closer to a new response to obesity, thanks in part to a study conducted by a team that included Sergio Iñiguez, Ph.D., associate professor of psychology at The University of Texas at El Paso.
The 10-member team led by Brandon Warren, Ph.D., assistant professor of pharmacodynamics at the University of Florida, made discoveries about a specific area of the brain tied to recollection and the desire to seek and consume food. It could lead to a way to inhibit the desire to overeat.
Iñiguez, who directs UTEP's Iñiguez Behavioral Neuroscience Lab and helped design novel experimental techniques for the research, said that people tend to overeat when exposed to cues or environments that remind them of treats, which is one reason ...
2021-02-12
BUFFALO, N.Y. - Humpback and bowhead whales are the only mammals other than humans thought to progressively change the songs they sing through a process of cultural learning.
But maybe the humpbacks are no longer part of that trio. Humpbacks might be singing songs that are not as "cultured" as once assumed.
A new study by a University at Buffalo researcher is directly contradicting the widely accepted cultural transmission hypothesis suggesting that whales learn their songs from other whales.
"It seems like that is not correct," says Eduardo Mercado, a professor of psychology in UB's College of Arts and Sciences. "Our findings indicate that neither cultural transmission nor social learning contributes significantly to how humpback whales ...
LAST 30 PRESS RELEASES:
[Press-News.org] New class of drug leads to 30% reduced risk of death for bladder cancer patients
A new type of drug that helps target chemotherapy directly to cancer cells has been found to significantly increase survival of patients with the most common form of bladder cancer, according to results from a phase III clinical trial
